<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01765790</url>
  </required_header>
  <id_info>
    <org_study_id>391101</org_study_id>
    <secondary_id>2013-002870-31</secondary_id>
    <nct_id>NCT01765790</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors</brief_title>
  <official_title>A Phase 1 Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-MIF Antibody in Subjects With Malignant Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety, tolerability, pharmacokinetics, and&#xD;
      pharmacodynamics of anti-MIF antibody in subjects with malignant solid tumors (Arm 1) and in&#xD;
      subjects with metastatic adenocarcinoma of the colon or rectum (Arm 2).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2012</start_date>
  <completion_date type="Actual">July 28, 2016</completion_date>
  <primary_completion_date type="Actual">July 28, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing serious adverse events (SAEs) and/or adverse events (AEs) regardless of causality</measure>
    <time_frame>14 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetic parameters</measure>
    <time_frame>28 days</time_frame>
    <description>Maximum concentration (Cmax), minimum concentration (Cmin), area under the concentration vs time curve (AUC), half-life [t½], clearance (CL), mean residence time (MRT) and volume of distribution at steady state (VDss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of free active MIF and free total MIF in plasma and tumor tissue (where applicable)</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in levels of tumor-associated biomarkers, if applicable based on cancer type, following treatment with anti-MIF antibody</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse events (SAEs) and/or adverse events (AEs), regardless of causality</measure>
    <time_frame>14 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing related serious adverse events (SAEs) and/or adverse events (AEs)</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of related serious adverse events (SAEs) and/or adverse events (AEs)</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of dose limiting toxicities (DLTs)</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing dose limiting toxicity (DLT)</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who develop binding and/or neutralizing anti-anti-macrophage migration inhibitory factor (anti-MIF) antibodies following treatment with anti-MIF</measure>
    <time_frame>14 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-MIF antibody in tumor tissues, bound and/or unbound to active MIF (where applicable)</measure>
    <time_frame>14 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of other potential biomarkers in tumor tissue (where applicable)</measure>
    <time_frame>14 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Metastatic Adenocarcinoma of the Colon or Rectum</condition>
  <condition>Malignant Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Malignant Solid Tumor (Arm 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation Phase- Standard dose escalation of anti-MIF antibody in 5 dose groups of 3-6 participants each according to 3+3 design: 1. Dose escalation will be performed after safety data review, following completion of dosing of each cohort. -&gt; 2. Safety data review. If dose escalation permissible -&gt; 3. Next dose group -&gt; 4. Safety data review, etc.&#xD;
Dose Expansion Phase- Enrollment of up to 6 participants to receive anti-MIF antibody (at the maximum tolerated dose or lower) in order to gain further experience with the investigational product at a specific dose level(s).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metastatic Adenocarcinoma of the Colon or Rectum (Arm 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation Phase- Standard dose escalation of anti-MIF antibody in 3 dose groups of 3-6 participants each according to 3+3 design: 1. Dose escalation will be performed after safety data review, following completion of dosing of each cohort. -&gt; 2. Safety data review. If dose escalation permissible -&gt; 3. Next dose group -&gt; 4. Safety data review, etc.&#xD;
Dose Expansion Phase- Enrollment of up to 6 participants to receive anti-MIF antibody (at the maximum tolerated dose or lower) in order to gain further experience with the investigational product at a specific dose level(s).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody</intervention_name>
    <description>Dosing every 2 weeks&#xD;
Intravenous injection</description>
    <arm_group_label>Malignant Solid Tumor (Arm 1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody</intervention_name>
    <description>Dosing weekly&#xD;
Intravenous injection</description>
    <arm_group_label>Metastatic Adenocarcinoma of the Colon or Rectum (Arm 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Males and females 18 years of age and older at the time of screening&#xD;
&#xD;
          -  Anticipated life expectancy &gt; 3 months at the time of screening&#xD;
&#xD;
          -  Arm 1 only: Histologically confirmed malignant solid tumor which is refractory to or&#xD;
             has failed standard treatments, or participant is not considered medically suitable to&#xD;
             receive standard of care treatment or refuses standard of care treatment&#xD;
&#xD;
          -  Arm 2 only: Histologically or cytologically confirmed diagnosis of metastatic&#xD;
             adenocarcinoma of the colon or rectum which is refractory to or has failed standard&#xD;
             treatments, or participant is not considered medically suitable to receive standard of&#xD;
             care treatment or refuses standard of care treatment&#xD;
&#xD;
          -  Measurable or evaluable disease (as defined in the study protocol)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1&#xD;
&#xD;
          -  Adequate hematological function (as defined in the study protocol)&#xD;
&#xD;
          -  Adequate renal function (as defined in the study protocol)&#xD;
&#xD;
          -  Adequate liver function (as defined in the study protocol)&#xD;
&#xD;
          -  Adequate venous access&#xD;
&#xD;
          -  Arm 2 only: At least 1 tumor that is amenable to biopsy, as determined by the&#xD;
             investigator, and participant must be willing to undergo a biopsy prior to and at&#xD;
             least once following anti-macrophage migration inhibitory factor (anti-MIF) antibody&#xD;
             treatment&#xD;
&#xD;
          -  For women of childbearing potential, the participant must have a negative pregnancy&#xD;
             test at screening and must agree to employ 2 forms of adequate contraceptive measures&#xD;
&#xD;
          -  For males, participants must agree to use adequate contraceptive measures including at&#xD;
             least 1 barrier method, and abstain from sperm donation throughout the course of the&#xD;
             study and for at least 90 days after the last administration of investigational&#xD;
             product.&#xD;
&#xD;
          -  Participant is willing and able to comply with the requirements of the protocol&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Known brain tumors or Central nervous system (CNS) metastases&#xD;
&#xD;
          -  Myocardial infarction within 6 months of anti-MIF antibody administration, congestive&#xD;
             heart failure (New York Heart Association Class III or Class IV), unstable angina,&#xD;
             unstable cardiac arrhythmia requiring medication, or risk factors for polymorphic&#xD;
             ventricular tachycardia&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &lt;40%, as determined by screening&#xD;
             echocardiogram (echocardiogram results obtained within 90 days prior to screening are&#xD;
             acceptable)&#xD;
&#xD;
          -  QT/QTc interval &gt;450 msec, as determined by screening electrocardiogram (ECG)&#xD;
&#xD;
          -  Antitumor therapy (chemotherapy, radiotherapy, antibody therapy, molecular targeted&#xD;
             therapy, retinoid therapy, or hormonal therapy) within 4 weeks prior to administration&#xD;
             of the investigational product (IP) (6 weeks for nitrosoureas and mitomycin C). Any&#xD;
             previous treatment-related toxicities must have recovered to Grade ≤ 1 (graded&#xD;
             according to the National Cancer Institute Common Terminology Criteria for Adverse&#xD;
             Events (NCI CTCAE) v4.03). Prior and concurrent use of hormone deprivation therapies&#xD;
             for hormone-refractory prostate cancer or breast cancer are permitted.&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to IP administration&#xD;
&#xD;
          -  Active joint inflammation or history of inflammatory arthritis or other immune&#xD;
             disorder involving the joints&#xD;
&#xD;
          -  Active infection requiring IV antibiotics within 2 weeks prior to screening&#xD;
&#xD;
          -  Known history of hepatitis B virus (HBV), hepatitis C virus (HCV), or active&#xD;
             tuberculosis. Known history of human immunodeficiency virus (HIV) type 1/2 or other&#xD;
             immunodeficiency disease.&#xD;
&#xD;
          -  Participant has received a live vaccine within 4 weeks prior to screening&#xD;
&#xD;
          -  Known hypersensitivity to any component of recombinant protein production by Chinese&#xD;
             Hamster Ovary (CHO) cells&#xD;
&#xD;
          -  Participant has been exposed to an investigational product (IP) or investigational&#xD;
             device in another clinical study within 4 weeks prior to IP administration, or is&#xD;
             scheduled to participate in another clinical study involving an IP or investigational&#xD;
             device during the course of this study&#xD;
&#xD;
          -  Participant is nursing or intends to begin nursing during the course of the study&#xD;
&#xD;
          -  Any disorder or disease, or clinically significant abnormality on laboratory or other&#xD;
             clinical test(s), that in medical judgment may impede the participant's participation&#xD;
             in the study, pose increased risk to the participant, or confound the results of the&#xD;
             study&#xD;
&#xD;
          -  Participant is a family member or employee of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scottsdale Healthcare</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists / Sarah Cannon Research Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Investigator Cancer Therapeutics, University of Texas, MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy and Research Center (CTRC), The University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 9, 2013</study_first_submitted>
  <study_first_submitted_qc>January 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2013</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

